Comparison of neoadjuvant chemotherapy followed by surgery (NAC) with adjuvant chemotherapy following surgery (ADJ), and NAC with definitive chemoradiotherapy for locally advanced esophageal cancer patients

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Yasuhiro Tsubosa

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

Y. Tsubosa1, M. Niihara2, K. Takebayashi2, A. Shimada2, H. Yasui3, T. Tsushima3, T. Yokota3

Author affiliations

  • 1 Division Of Esophageal Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Esophageal Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 3 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
More

Resources

Aim/Background

We decided to compare oncological outcome of neoadjuvant chemotherapy followed by surgery (NAC) with adjuvant chemotherapy following surgery (ADJ), and NAC with definitive chemoradiotherapy for locally advanced esophageal cancer patients.

Methods

Consecutive patients histologically diagnosed with ESCC and planned to undergo NAC, ADJ and dCRT as initial treatment were eligible for this retrospective study. In ADJ, NAC and dCRT group, overall survival and non complete resection rate were investigated. We analyzed in intent-to-treat analysis.

Results

98 patients included in NAC group, 90 were included in ADJ group, and 47 were included in dCRT group. No significant differences were observed in clinicopathological factors among NAC group (cStage IB/II/III/IV = 10/28/52/8) and ADJ group (cStage IB/II/III/IV = 6/22/57/5) and dCRT group (cStage IB/II/III/IV = 3/15/20/7). In intention-to-treat analysis, there was no significant difference in 3yOS rate by NAC group and ADJ group (NAC group, 66%; ADJ group, 67%; p = 0.301). However, non complete resection rate was significantly higher for NAC group than for ADJ group (ADJ group, 3.3%; NAC group, 16.7%; p = 0.009). In cStage III, non complete resection rate of ADJ group was 3.5% and NAC group was 25%. In the patients with cStage III, NAC group had a tendency for 3yOS rate to be low rather than ADJ group (NAC group, 51.1%; ADJ group, 66.3%; p = 0.09). In intention-to-treat analysis, there was no significant difference in relapse free survival between NAC group and dCRT group. In contrast, the rate of 3yOS tend to be higher in the NAC group than the dCRT group (NAC, 66.0%; dCRT, 49.8%; p = 0.166). After initial treatment failure, significantly more patients could undergo local treatment in NAC group than dCRT group (NAC, 74%; dCRT, 40%; P = 0.003).

Conclusions

In ESCC patients who could tolerate transthoracic esophagectomy, no significant difference was observed in survival between the NAC and dCRT groups. However, NAC group was extended short-term survival (3yOS), which might have been encouraged by utilizing local treatment after initial treatment failure.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings